688221 Frontier Biotechnologies Inc.
- 8.99
- -0.29-3.13%
Frontier Biotechnologies Inc. News
Legal Opinion of Beijing Guofeng (Nanjing) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Frontier Biopharmaceuticals (Nanjing) Co., Ltd.
Announcement of Resolutions of Frontier Biotech\'s 2024 Fourth Extraordinary General Meeting of Shareholders
Frontier Biotech Announces Election of Staff Representative Supervisors for the 4th Board of Supervisors
Frontier Biotech\'s announcement on the completion of the election of the Board of Directors and the Board of Supervisors and the appointment of senior management and securities affairs representatives
Frontier Biotech: Frontier Biotech 2024 4th Extraordinary General Meeting of Shareholders Meeting Information
Frontier Biotech 2024 Fourth Extraordinary General Meeting of Shareholders Meeting Information
Frontier Biology: Frontier Biotech\'s announcement on the election of the Board of Directors and Supervisory Board for new terms
Frontier Biology: Frontier Biotech Independent Director Candidate Statements and Commitments - Geng Qiang
Frontier Biology: Frontier Biotech Independent Director Nominee Statement and Commitment - You Qidong
Frontier Biology: Frontier Biotech Independent Director Candidate Statement and Commitment - You Qidong
Frontier Biology: Frontier Biotech Independent Director Nominee Statement and Commitment - Geng Qiang
Frontier Biology: Opinions of the Nomination Committee of the Board of Directors of Frontier Biopharmaceuticals (Nanjing) Co., Ltd. on candidates for independent directors of the 4th board of directors
Frontier Biology: Frontier Biotech Independent Director Candidate Statement and Commitment - Wang Sumei
Frontier Biology: Frontier Biotech Independent Director Nominee Statement and Commitment - Wang Sumei
Frontier Biotech: Frontier Biotech\'s Notice on Convening the Fourth Extraordinary General Meeting of Shareholders in 2024
Frontier Biotech\'s announcement on the election of the board of directors and board of supervisors
Notice of Frontier Biotech on convening the 4th Extraordinary General Meeting of Shareholders in 2024
Frontier Biotech\'s announcement on the renewal of the company\'s product Aikenin\'s contract to enter the national medical insurance catalogue
Frontier Biotech\'s announcement on the progress of the sale of part of its wholly-owned subsidiary shares and the issuance of business licenses by the subsidiary
Frontier Biotech Voluntary Disclosure Notice Regarding New Indications for Maintenance Treatment of Iconin® Obtaining Approval Letter for Phase II Clinical Trials
No Data
